(o) (4 Cleaning ofGrade areas used in the manufacture ofCASGEVY drug product is deficient.
Inspection Record
Lonza Portsmouth, Inc. — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
Each batch of drug product purporting to be sterile and/or pyrogen-free is not adequately tested to determine conformance to such requirements.
The following practices that are inconsistent with Good Documentation Practices were observed: a.
Pest control program is deficient.
Environmental monitoring and control are deficient.
Aseptic processing ofCASGEVY drug product is deficient.
Management of deviations and anomalous events is inadequate to identify root causes and appropriate corrective § actions.
Heating, ventilation, and air conditioning maintenance and controls are inadequate.
Areas designed to (b) (4) in a biological safety cabinet are deficient regarding characterization and mapping of the areas and operations for aseptic processing ofdrug products.
A record as of the US FDA document published on 2026-10-20. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.